Takeda buying into Schizophrenia company! great news!

[Anonymous]

Takeda is going to be getting into the Schizophrenia market! That means there are going to have to create a brand new sales force that can sell CNS products!! How cool is that? Just in time with Actos going bye bye!

 

[Anonymous]

Where did you hear this? Why do I think they would never let the existing sales force sell any potential new CNS drug?

 

[Anonymous]

The link......

http://seekingalpha.com/article/256...izophrenia-partnership-biotech-s-latest-deals

 

[Anonymous]

Press Release

FOR IMMEDIATE RELEASE

Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
NEW YORK and OSAKA, Japan, March 2, 2011 / PRNewswire / -- Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda"), today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States. ITI's PDE1 inhibitors are unique, orally available, preclinical stage compounds. These compounds have potential to be treatments for a variety of psychiatric and neurological diseases.

Under the terms of the agreement, ITI will receive an upfront cash payment and will be eligible to receive payments of approximately $500 million in the aggregate upon achievement of certain development milestones and up to an additional $250 million in the aggregate upon achievement of certain sales-based milestones, along with tiered royalty payments based on net sales by Takeda. Takeda will be solely responsible for development, manufacturing and commercialization of PDE1 inhibitors.

"Takeda's strength in CNS drug development and commercialization complements ITI's innovative approach to discovery, research and development," said Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc. "We are delighted to be working together with Takeda to advance the development of our novel PDE1 inhibitors. This program represents a unique approach to the treatment of cognitive impairment associated with schizophrenia (CIAS) and other disorders."

"We are able to enhance our central nervous system pipeline, one of our Core Therapeutic Areas, through this collaboration," said Shigenori Ohkawa, a member of the Board and Executive Vice President, Chief Scientific Officer of Takeda Pharmaceutical Company Limited. "We believe that ITI's PDE1 inhibitors have the potential to be a novel drug with a new mechanism of action which will satisfy unmet medical needs for the millions of patients suffering from schizophrenia. We plan to accelerate our R&D activities for this compound in an effort to bring this novel medicine to patients as quickly as possible."

 

[Anonymous]

Where did you hear this? Why do I think they would never let the existing sales force sell any potential new CNS drug?

CNS is a tricky market. You need a specially trained force to properly sell a CNS product.

 

[Anonymous]

Takeda did such a good job launching rozerem in the CNS market. Glad to see we will get another shot at it!

 

[Anonymous]

Nice!

I hope we do launch it. Maybe the shitbag I work for will find his way into home office for a coveted PM role.

 

[Anonymous]

Takeda is going to be getting into the Schizophrenia market! That means there are going to have to create a brand new sales force that can sell CNS products!! How cool is that? Just in time with Actos going bye bye!

This is as idiotic as getting into the ARB market. All the major schizophrenia drugs are going off patent in the next year. Zyprexa, Seroquel and Geodon - the market leaders will all be generic within 18 months! Risperdal already went generic. Those product make up over 95% of the branded class of schizophrenia medications. My husbands brother works at Schering (now Merck) and he said everyone is leaving or have been downsized because the schizophrenia / antipsychotic market is dead with all those products going generic in a year. So, exactly how is this good?

 

[Anonymous]

This is as idiotic as getting into the ARB market. All the major schizophrenia drugs are going off patent in the next year. Zyprexa, Seroquel and Geodon - the market leaders will all be generic within 18 months! Risperdal already went generic. Those product make up over 95% of the branded class of schizophrenia medications. My husbands brother works at Schering (now Merck) and he said everyone is leaving or have been downsized because the schizophrenia / antipsychotic market is dead with all those products going generic in a year. So, exactly how is this good?

Once,just once,can someone say something slightly positive at all on this board?

 

[Anonymous]

This is as idiotic as getting into the ARB market. All the major schizophrenia drugs are going off patent in the next year. Zyprexa, Seroquel and Geodon - the market leaders will all be generic within 18 months! Risperdal already went generic. Those product make up over 95% of the branded class of schizophrenia medications. My husbands brother works at Schering (now Merck) and he said everyone is leaving or have been downsized because the schizophrenia / antipsychotic market is dead with all those products going generic in a year. So, exactly how is this good?

Of course, a lot of analysis goes into these strategic moves that you are not privy to. Someone somewhere crunches the numbers and forecasts profits for a venture like this. Takeda isnt being run by idiots ya know.

 

[Anonymous]

OTakeda isnt being run by idiots ya know.

Really ???????

 

[Anonymous]

Of course, a lot of analysis goes into these strategic moves that you are not privy to. Someone somewhere crunches the numbers and forecasts profits for a venture like this. Takeda isnt being run by idiots ya know.

Yes, you are right. The strategy here is nothing short of amazing. I'm sure we know what we're doing. Like when we paid millions to get a cut of contrave. Or when we paid millions for a share of an ARB. Or when we spent hundreds of millions to bring Dexilant to market and thought it would be a billion dollar a year product. Or the millions we spent on Rozerem (add to that the hundreds of millions we spent on advertising for rozerem and the product never grossed as much as we spent on adds. genius). Or the hundreds of millions we're spending on Uloric advertising right now. Looks like we're following the rozerem template on that one.

So I beg to differ with your posts. Takeda is being run by idiots and has been for some time.

 

[Anonymous]

Well if they're all so dumb, how come the people who ran those product teams keep getting promoted? Oh wait, the inmates are running the asylum here. Never mind.

 

[Anonymous]

Once,just once,can someone say something slightly positive at all on this board?

OK. Here goes. I got laid again this weekend. It was truly a life changer.

 

[Anonymous]

Let us also add the Kapodex name fiasco into another monument of stupidity. How much money was lost from that whole name change debacle?

 

[Anonymous]

Another bad decision....how about advertising all of takeda's products on cafepharma under their own company's boards. Another great decision from executives and marketing. I thought the object of sales was to sell products to others not your own company...Money well spent.

 

[Anonymous]

Let us also add the Kapodex name fiasco into another monument of stupidity. How much money was lost from that whole name change debacle?

Better question still,how many jobs were lost because of these knuckleheads!!!!!

 

[Anonymous]

Once,just once,can someone say something slightly positive at all on this board?

There is NOTHING positive going on at Takeda anymore!!!!!That era,that feeling is gone forever!

 

[Anonymous]

Takeda is going to be getting into the Schizophrenia market! That means there are going to have to create a brand new sales force that can sell CNS products!! How cool is that? Just in time with Actos going bye bye!

Actullay it is so they can treat their leadership team for free.